\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe MSCA unit of Directorate-General for Education, Youth, Sport and Culture of the European Commission will start with the MSCA ‘Fellow of the month’ communication initiative, which will present testimonials from current and former MSCA fellows. It will offer insight into their scientific achievements, personal experiences, and the broader contribution of their projects to society. The aim is to reflect the diversity and excellence of the MSCA community - across countries, disciplines and sectors.
The selected testimonials will be published on a monthly basis, and in connection with key EU policy themes, international or European days, and relevant science communication moments throughout the year. In this way, the initiative will help bring MSCA-funded research closer to citizens and demonstrate how it contributes to European priorities and global challenges.
To select the fellows, a call for nominations is now open. Nominations can be submitted via a short online form. Nominations are welcome from supervisors, colleagues and fellows themselves. The submissions deadline is 11 May 2025 at 12.00, CEST.
Fellows will be chosen by the European Commission based on criteria including
This call has been announced in the news section on the European Commission MSCA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
